Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898545 | 0.91 | POLB (0.34) | LMNASHMT2MEN1POLBPABPC1 | |
| SCHEMBL4906169 | 0.91 | ALDH1A1 (0.38) | LMNAMEN1POLBPABPC1KMT2A | |
| SCHEMBL4909342 | 0.90 | ALDH1A1 (0.35) | MEN1POLBPABPC1KMT2AMAPT | |
| SCHEMBL4900456 | 0.89 | ALDH1A1 (0.33) | MEN1POLBPABPC1KMT2AMAPT | |
| SCHEMBL14067537 | 0.88 | ALDH1A1 (0.37) | LMNAMEN1POLBPABPC1KMT2A | |
| SCHEMBL4907852 | 0.87 | ALDH1A1 (0.38) | LMNAMEN1POLBPABPC1KMT2A | |
| SCHEMBL4904317 | 0.86 | MEN1 (0.35) | SHMT2MEN1POLBPABPC1KMT2A | |
| SCHEMBL14067570 | 0.86 | ALDH1A1 (0.35) | LMNAMEN1POLBPABPC1KMT2A | |
| SCHEMBL4903149 | 0.86 | ALDH1A1 (0.36) | MEN1POLBPABPC1KMT2AMAPT | |
| SCHEMBL4907766 | 0.86 | ALDH1A1 (0.36) | LMNAMEN1POLBPABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | LMNA 4059/4885SHMT2 1189/4885MEN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.